Clinical characteristics of chronic hepatitis B virus patients treated by immunosuppressive therapy without lamivudine prophylaxis
| Patient . | Sex . | Age, y . | Basic disease . | Immunosuppressive treatment . | Outcome . |
|---|---|---|---|---|---|
| A | M | 46 | Lymphoma | High-dose MACOP-B*,† | Died |
| B | M | 59 | Lymphoma | CHOP,†MOPP‡ | Died |
| C | M | 18 | Malignant | CHOP,† high-dose | Died |
| histocytosis | methotrexate | ||||
| D | M | 56 | Lymphoma | CHOP† | Alive |
| E | M | 67 | Lymphoma | MOPP,‡ABVD2-153 | Alive |
| Patient . | Sex . | Age, y . | Basic disease . | Immunosuppressive treatment . | Outcome . |
|---|---|---|---|---|---|
| A | M | 46 | Lymphoma | High-dose MACOP-B*,† | Died |
| B | M | 59 | Lymphoma | CHOP,†MOPP‡ | Died |
| C | M | 18 | Malignant | CHOP,† high-dose | Died |
| histocytosis | methotrexate | ||||
| D | M | 56 | Lymphoma | CHOP† | Alive |
| E | M | 67 | Lymphoma | MOPP,‡ABVD2-153 | Alive |
MACOP-B consists of methotrexate (1145 mg/m2); doxorubicin [Adriamycin] (275 mg/m2); cyclophosphamide (1875 mg/m2); bleomycin (28 mg/m2).
See Table 1 footnote for the CHOP regimen.
The MOPP regimen was as follows: mechlorethamine (6 mg/m2), days 1, 8; vincristine (Oncovin) (1.4 mg/m2), days 1, 8; procarbazine 100 mg/m2, days 1-14; prednisone 40 mg/m2, days 1-14.
The ABVD regimen was as follows: doxorubicin [Adriamycin] (25 mg/m2), days 1, 15; bleomycin (10 mg/m2), days 1, 15; vinblastine (6 mg/m2), days 1, 15; dacarbazine (150 mg/m2) days 1, 15.